184 related articles for article (PubMed ID: 21264447)
1. Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice.
Ramezani A; Zweier-Renn LA; Hawley RG
Thromb Haemost; 2011 Apr; 105(4):676-87. PubMed ID: 21264447
[TBL] [Abstract][Full Text] [Related]
2. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
[TBL] [Abstract][Full Text] [Related]
4. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
6. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
7. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
[TBL] [Abstract][Full Text] [Related]
8. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
Van Damme A; Chuah MK; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
[TBL] [Abstract][Full Text] [Related]
10. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
11. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
[TBL] [Abstract][Full Text] [Related]
14. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
15. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
16. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
19. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.
Gangadharan B; Parker ET; Ide LM; Spencer HT; Doering CB
Blood; 2006 May; 107(10):3859-64. PubMed ID: 16449528
[TBL] [Abstract][Full Text] [Related]
20. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.
Ramezani A; Hawley RG
Blood; 2009 Jul; 114(3):526-34. PubMed ID: 19470695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
